Familial amyloid polyneuropathy (FAP) or transthyretin (TTR) amyloid neuropathy
are a rare group of autosomal dominant diseases caused by the deposition of protein and/or amyloid fibrils around the peripheral nerves and in various tissues, including the heart muscle. Symptoms for the disorder include limb weakness, and loss of sensation in case of peripheral neuropathy, bowel disturbance and sexual dysfunction in case of autonomic neuropathy. The most successful cure for the disorder is liver transplant, however Europe has approved a drug named Vyndaqel (tafamidis) by Pfizer Inc. and is under Phase III clinical trials to seek U.S. FDA approval. Globally, development of new drugs for treatment of familial amyloid polyneuropathy, and rise in the prevalence of familial amyloid polyneuropathy are the prime growth drivers of familial amyloid polyneuropathy market. In addition, increase in adoption of familial amyloid polyneuropathy drugs, and emerging economies such as China, India and others will create new opportunities for the familial amyloid polyneuropathy market. However, higher cost of the research and development, and treatment, and stringent government regulations are the key restraints for the familial amyloid polyneuropathy market.
This report identifies the
global familial amyloid polyneuropathy market
size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to the global familial amyloid polyneuropathy market.
Geographically, Europe dominates the familial amyloid polyneuropathy market, and Asia Pacific is projected to have the fastest growth, owing to rapidly increasing aging population and modernizing healthcare infrastructure in this region. Among all the categorises, peripheral sensorimotor polyneuropathy has the highest market share in the familial amyloid polyneuropathy market.
This report segments familial amyloid polyneuropathy market on the basis of type, category, and regional market as follows:
- Familial Amyloid Polyneuropathy Market, By Type: Familial Amyloid Polyneuropathy-I (FAP-I), Familial Amyloid Polyneuropathy-II (FAP-II), Familial Amyloid Polyneuropathy-III (FAP-III), and Familial Amyloid Polyneuropathy-IV (FAP-IV)
- Familial Amyloid Polyneuropathy Market, By Category: Peripheral Sensorimotor Polyneuropathy, and Autonomic Nervous System Dysfunction
- This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the familial amyloid polyneuropathy market. Some of the major companies’ profiles in detail are as follows:
- Pfizer Inc.
- GlaxoSmithKline plc
- Ionis Pharmaceuticals